An interventional study of Guduchi Ghanvati and Standard guidelines in Covid19, sponsored by NMP Medical Research Institute. Completed at 2 sites in India. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-10.
Sponsored by NMP Medical Research Institute · Not applicable, Interventional, and Prevention
Specifically identified Ayurvedic preparations is recommended by ministry of AYUSH as post-exposure prophylaxis to efficaciously prevent a negative person who has come into contact with COVID-19-positive. Traditionally, recommended Ayurvedic preparations have been used as antioxidants, antimicrobial and anti-inflammatory properties. Particularly, Guduchi Ghanvati has been recognised with its ability to control viral attachment, viral replication and induce immune response in pre clinical settings, and found to be one among the most important drugs in Ayurveda to fight against COVID-19.
However, known gap in guideline implementation and its impact on preventing active infection in exposed cases is unclear. Study aimed to increase the use of recommended AYUSH guidelines by having registered AYUSH physicians provide these medications, when indicated, in community based participants after known exposure to the SARS-CoV-2 coronavirus.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 216 is above the median of 100 across 4,099 interventional studies indexed under COVID-19.
Browse COVID-19 studies →NMP Medical Research Institute is the lead sponsor of 30 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask Samshamani vati or Giloy Ghanavati
Other: Guduchi Ghanvati · Other: Standard guidelines
Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask
Other: Standard guidelines
500 mg of Samshamani vati or Giloy Ghanavati (Aqueous extract of Tinospora cordifolia) twice daily
Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask
Number of participants with active COVID-19
PCR- proven COVID-19
Time frame: 14-days following exposure
Time to symptoms onset
Days until start of symptoms of COVID-19
Time frame: 14-days
Disease Severity
Visual Analog Scale of rating overall symptom severity (0 = no symptoms; 10 = most severe)
Time frame: 14 days
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NMP Medical Research Institute